Kura Oncology, Inc. - Common Stock (KURA)

Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant decline marks a notable correction for the biotechnology company, which had seen its stock surge dramatically in the preceding days,

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

These two healthcare growth stocks could have a lot more room to run.

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA submission set for Q2 2025.

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Instead of seeking a takeover, the company inked a deal worth up to $1.53 billion for its lead asset.

KURA stock results show that Kura Oncology beat analyst estimates for earnings per share the second quarter of 2024.

Although death cross stocks sound incredibly ominous, they could be the ideal time to consider a contrarian position.